|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT03151460 |
|
Date of registration:
|
09/05/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Dopaminergic Modulation of Declarative Memory
|
|
Scientific title:
|
Dopaminergic Modulation of Declarative Memory |
|
Date of first enrolment:
|
September 2014 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03151460 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
Italy
| | | | | | | |
|
Contacts
|
|
Name:
|
Giovanni Carlesimo, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Fondazione S. Lucia |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson Disease made by a neurologist according to the
London Brain Bank criteria.
Exclusion Criteria:
- disease duration = 5 years; diagnosis of dementia based on clinical criteria and
confirmed by a Mini-Mental State Examination score < 26; presence of other
neurological and/or psychiatric illnesses in the patient's clinical history.
Age minimum:
N/A
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Parkinson's Disease
|
|
Intervention(s)
|
|
Drug: Dopamine Agent
|
|
Primary Outcome(s)
|
|
Performance on cognitive task
[Time Frame: 60 min.]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|